Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016" report to their offering.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 13 molecules, out of which approximately 9 molecules are developed by Companies and the remaining by the Universities/Institutes. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 6 and 1, respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2016, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development, and features dormant and discontinued projects and the latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Gastric Inhibitory Polypeptide Receptor Overview
  3. Therapeutics Development
  4. Pipeline Products for Gastric Inhibitory Polypeptide Receptor - Overview
  5. Pipeline Products for Gastric Inhibitory Polypeptide Receptor - Comparative Analysis
  6. Gastric Inhibitory Polypeptide Receptor - Therapeutics under Development by Companies
  7. Gastric Inhibitory Polypeptide Receptor - Therapeutics under Investigation by Universities/Institutes
  8. Gastric Inhibitory Polypeptide Receptor Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Gastric Inhibitory Polypeptide Receptor - Products under Development by Companies
  13. Gastric Inhibitory Polypeptide Receptor - Products under Investigation by Universities/Institutes
  14. Gastric Inhibitory Polypeptide Receptor - Companies Involved in Therapeutics Development
  • Alchemia Limited
  • AstraZeneca Plc
  • Carmot Therapeutics Inc.
  • Diabetica Limited
  • Eli Lilly and Company
  • Longevity Biotech Inc.
  • Sanofi
  • Zealand Pharma A/S

For more information about this report visit http://www.researchandmarkets.com/research/599z9f/gastric.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006411/en/

Business Wire
www.businesswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.